evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,125 questions · 1,173 findings · 91 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 192 · 16.4%GRADE not reported 47 · 4%Very low 199 · 17%Low 325 · 27.7%Moderate 271 · 23.1%High 139 · 11.8%

Non‐platinum therapies vs platinum combination

Grade 3 or higher hematological toxicity for platinum therapies ‐ anemia · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).

1 finding from 1 review

Non‐platinum therapies vs platinum combination

Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).

1 finding from 1 review

Non‐platinum therapies vs platinum combination

Grade 3 or higher Non‐Hematological Toxicity for Platinum‐based therapies ‐ Peripheral neuropathy · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to higher grade 3 or higher Non‐Hematological Toxicity for Platinum‐based… compared with platinum combination (low certainty).

1 finding from 1 review

Non‐platinum single‐agent vs non‐platinum combination treatment

Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population

It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).

1 finding from 1 review

Non‐platinum single‐agent vs non‐platinum combination treatment

Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population

Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).

1 finding from 1 review

Non‐platinum single‐agent vs non‐platinum combination treatment

Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · non‐small cell lung cancer in the elderly population

It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia compared with non‐platinum combination treatment (very low certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in numbers of participants with at least 1 clinically significant… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in number of participants with WHO Grade 3 or 4 bleeding up to 30 days… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Time to first bleeding episode (days) · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in time to first bleeding episode (days) compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Mortality from all causes up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality from all causes up to 30 days from study entry compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review